🇺🇸 valganciclovir [Valcyte] in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Abdominal Pain — 1 report (10%)
- Acinetobacter Test Positive — 1 report (10%)
- Anaemia — 1 report (10%)
- Back Pain — 1 report (10%)
- Blood Creatine Increased — 1 report (10%)
- Blood Lactate Dehydrogenase Increased — 1 report (10%)
- Blood Lactic Acid Increased — 1 report (10%)
- Complication Associated With Device — 1 report (10%)
- Cytokine Release Syndrome — 1 report (10%)
- Cytomegalovirus Infection — 1 report (10%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is valganciclovir [Valcyte] approved in United States?
valganciclovir [Valcyte] does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for valganciclovir [Valcyte] in United States?
Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.